Article
Association of CYP2C9*2 with bosentan-induced liver injury.
Clinical pharmacology and therapeutics - 1 Dec 2013
Markova S M, De Marco T, Bendjilali N, Kobashigawa E A, Mefford J, Sodhi J, Le H, Zhang C, Halladay J, Rettie A E, Khojasteh C, McGlothlin D, Wu A H B, Hsueh W-C, Witte J S, Schwartz J B, Kroetz D L
Abstract excerpt
Bosentan (Tracleer) is an endothelin receptor antagonist prescribed for the treatment of pulmonary arterial hypertension (PAH). Its use is limited by drug-induced liver injury (DILI). To identify genetic markers of DILI, association analyses were performed on 56 Caucasian PAH patients receiving bosentan. Twelve functional polymorphisms in five genes (ABCB11, ABCC2, CYP2C9, SLCO1B1, and SLCO1B3) implicated in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.